RESEARCH ARTICLE

HIV and HAART-Associated Dyslipidemia

The Open Cardiovascular Medicine Journal 24 Feb 2011 RESEARCH ARTICLE DOI: 10.2174/1874192401105010049

Abstract

Effective highly active antiretroviral therapy (HAART) for human immunodeficiency virus-1 (HIV) infection has led to marked improvement in life-expectancy for those infected with HIV. Despite reductions in the incidence of AIDS with effective treatment, patients continue to experience considerable morbidity and mortality from non-AIDS illness such as premature cardiovascular disease, liver failure and renal failure. These morbidities, particularly premature cardiovascular disease, are thought to be related to a combination of the effects of an ageing HIV-infected population coupled with long-term effects of HIV infection and antiretroviral therapy (ART). One of the principle drivers behind the well documented increase in the risk of cardiovascular disease in HIV-infected patients is dyslipidemia.

This review will focus on the clinical presentation of HIV and ART-associated dyslipidemia, what is known of its patho-physiology, including associations with use of specific antiretroviral medications, and suggest screening and management strategies.

Keywords: HIV, HAART, dyslipidemia, cholesterol, triglycerides, lipids..
Fulltext HTML PDF
1800
1801
1802
1803
1804